Abvc Biopharma (ABVC) Total Non-Current Liabilities (2019 - 2026)

Abvc Biopharma (ABVC) has reported Total Non-Current Liabilities for 8 consecutive years, with $7.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities rose 5.82% year-over-year to $7.1 million; the trailing twelve-month figure through Jun 2026 stood at $7.1 million (up 5.82% YoY), and the FY2025 full-year result was $122508.0, up 6.89% from the prior year.
• Total Non-Current Liabilities grew to $7.1 million in Q2 2026 per ABVC's latest filing, from $122508.0 in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $7.1 million in Q2 2026 and bottomed at $100261.0 in Q3 2022.
• Historically, Total Non-Current Liabilities has averaged $2.4 million across 5 years, with a median of $357150.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities slumped 92.4% in 2023, then jumped 6668.58% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $103447.0 in 2022, then jumped by 235.62% to $347193.0 in 2023, then tumbled by 66.99% to $114606.0 in 2024, then advanced by 6.89% to $122508.0 in 2025, then jumped by 5695.53% to $7.1 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $7.1 million, $122508.0, and $6.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.